Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

Company Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis. The company also develops investigational RNAi medicines for diseases affecting the liver, cardiovascular system, central nervous system, and other areas.

The company serves patients and healthcare providers through commercial operations and partnerships in the United States and international markets. Alnylam has entered collaborations with pharmaceutical companies to support the development, manufacturing, and commercialization of certain products. Yvonne Greenstreet has served as Alnylam’s chief executive officer since 2022.

Key Stats

• Today's Range: $231.29 to $237.98
• 50-Day Range: $216.98 to $267.40
• 52-Week Range: $197.81 to $495.55
• Volume: 1.40 million shs
• Average Volume: 1.30 million shs
• Market Capitalization: $31.02 billion
• P/E Ratio: 43.09
• Dividend Yield: N/A
• Price Target: $364.95
• Consensus Rating: Moderate Buy

Alnylam Pharmaceuticals Stock Analysis - MarketRank™

Alnylam Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 76th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 4 strong buy ratings, 16 buy ratings, 6 hold ratings, and no sell ratings.

Upside Potential

Alnylam Pharmaceuticals has a consensus price target of $364.95, representing about 57.4% upside from its current price of $231.83.

Amount of Analyst Coverage

Alnylam Pharmaceuticals has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 45.36%

Earnings Growth

Earnings for Alnylam Pharmaceuticals are expected to grow by 45.36% in the coming year, from $6.68 to $9.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alnylam Pharmaceuticals is 43.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alnylam Pharmaceuticals is 43.09, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.39.

Price to Book Value per Share Ratio

Alnylam Pharmaceuticals has a P/B Ratio of 38.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.81% of the float of Alnylam Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 6.45.

Change versus previous month

Short interest in Alnylam Pharmaceuticals has recently increased by 7.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alnylam Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Alnylam Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.19

News Sentiment

Alnylam Pharmaceuticals has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Alnylam Pharmaceuticals this week, compared to 10 articles on an average week.

Search Interest

16 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.

MarketBeat Follows

7 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $398,855.00 in company stock.

Percentage Held by Insiders

0.86% of the stock of Alnylam Pharmaceuticals is held by insiders.

Percentage Held by Institutions

92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/18/2026
• Investor update: 10/26/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALNY
• CIK: 1178670
• Web: www.alnylam.com
• Phone: (617) 551-8200
• Fax: 617-551-8101
• Employees: 2,770
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Alnylam Pharmaceuticals: $364.95
• High Price Target: $489.00
• Low Price Target: $253.00
• Potential Upside/Downside: +57.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.38
• Trailing P/E Ratio: 43.09
• Forward P/E Ratio: 34.71
• P/E Growth: N/A
• Net Income: $313.75 million
• Net Margins: 15.26%
• Pretax Margin: 15.95%
• Return on Equity: 84.93%
• Return on Assets: 14.30%

Debt

• Debt-to-Equity Ratio: 0.75
• Current Ratio: 3.05
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $3.71 billion
• Price / Sales: 8.35
• Cash Flow: $2.80 per share
• Price / Cash Flow: 82.91
• Book Value: $5.97 per share
• Price / Book: 38.83

Miscellaneous

• Outstanding Shares: 133,810,000
• Free Float: 132,658,000
• Market Cap: $31.02 billion
• Optionable: Optionable
• Beta: 0.28